Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our San Diego lab seeks a motivated and enthusiastic structural biologist to enhance our expertise in X-ray crystallography, cryo-electron microscopy, and structure based drug design. The successful candidate will collaborate and/or lead multidisciplinary drug discovery projects, manage CRO resources and develop structural biology strategy.
Job Responsibilities/What you will do:
- Develop and implement structural biology strategies for drug discovery programs from target evaluation to candidate nomination
- Lead and coordinate structural biology research projects, including managing CRO activities
- Guide protein-small molecule complex structures to support structure-based drug design and platform evolution
- Collaborate with other drug discovery disciplines (biology, medicinal chemistry, DPMK, software engineers, computational chemists) to drive hypothesis driven decisions and enhance the platform
- Regularly communicate and engage with project team members and management
Education and Experience Requirements/What you'll bring:
- PhD in crystallography, cry-EM, biophysics, or relevant structural biology degree with 8+ years of industrial drug discovery experience or
- MS in structural biology with at least 14 years of industrial drug discovery experience
- Expertise in protein production, purification, X-ray crystallography and cryo-EM
- Experience across oncology and immunology targets
- Effective management of external CRO structural biology resources
- Strong understanding of molecular modeling and computational biology
- Proficiency in characterizing protein-ligand interactions using biophysical methods
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has three AI platform collaborations across a range of therapeutic areas, with Gilead Sciences, Eli Lilly, and Genentech.
We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Top Skills
What We Do
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery.
We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines.
Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price.
Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/
We deploy our technology to accelerate a pipeline of several internal drug programs.
Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.
Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets.
We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc.
We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline.
Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates.
Please apply on our website, or feel free to reach out via email directly: [email protected]
